Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD)
| Autor: | Norio Komatsu, Tomohiro Sawada, Haruko Takizawa, Yasunobu Sekiguchi, Keiji Sugimoto, Yasutaka Fukuda, Tadaaki Inano, Yasunori Ohta, Shigeki Tomita, Masaaki Noguchi, Noriko Nakamura, Mutsumi Wakabayashi, Hiroshi Izumi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Indoles Nausea medicine.medical_treatment Hydroxamic Acids Gastroenterology Dexamethasone Bortezomib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Recurrence Renal Dialysis Panobinostat Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Renal Insufficiency Adverse effect Multiple myeloma Aged business.industry Common Terminology Criteria for Adverse Events Hematology medicine.disease Surgery 030104 developmental biology chemistry Cardiac amyloidosis 030220 oncology & carcinogenesis Female Hemodialysis medicine.symptom business Multiple Myeloma medicine.drug |
| Zdroj: | International journal of hematology. 106(4) |
| ISSN: | 1865-3774 |
| Popis: | Three patients under hemodialysis (HD) with relapsed/refractory multiple myeloma (MM) were administered panobinostat/bortezomib/dexamethasone (FVD). Case 1: The patient was a 66-year-old male with BJP-κ. FVD was effective, but HD could not be discontinued. He developed Grade 3 adverse events (AEs), including nausea, dehydration, and fatigue, following the common terminology criteria for adverse events v4.0. FVD was discontinued after the third course, while HD was continued. Case 2: The patient was a 65-year-old female with IgG-λ + BJP-λ. Amyloidosis was complicated. The first course of FVD was effective, but HD could not be discontinued. She developed G2 AEs, including nausea and fatigue. The cardiac amyloidosis worsened, and she died of heart and renal failure. Case 3: The patient was a 79-year-old male with BJP-κ. FVD was effective, and the HD could be discontinued on day 12 of treatment. No AEs were noted. However, he declined continuation of the FVD and died of MM relapse and renal failure. We analyzed the pharmacokinetics of panobinostat. There were no correlations between dose level and blood level of panobinostat or between blood level, efficacy, and incidence of AEs. We additionally measured the rate of elimination of the drug by HD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink